71897-07-9
71897-07-9 结构式
基本信息
6,7-二甲基-2-苯基喹喔啉
酪氨酸磷酸化抑制剂AG1295
NSC 380341
AG 1295 USP/EP/BP
TYRPHOSTIN AG 1295
TYROPHOSTIN AG1295
AG-1295 (NSC 380341
TYRPHOSTIN AG 1295, 99+%
AG 1295 PLATELET-DERIVED GROW
6,7-DIMETHYL-2-PHENYLQUINOXALINE
Quinoxaline, 6,7-dimethyl-2-phenyl-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-101957 | 酪氨酸磷酸化抑制剂AG1295 AG 1295 | 71897-07-9 | 5mg | 600元 |
| 2024/04/30 | HY-101957 | 酪氨酸磷酸化抑制剂AG1295 AG 1295 | 71897-07-9 | 10mM * 1mLin DMSO | 660元 |
| 2024/04/30 | HY-101957 | 酪氨酸磷酸化抑制剂AG1295 AG 1295 | 71897-07-9 | 50mg | 3000元 |
常见问题列表
PDGFR
AG 1295 inhibits PDGFR autophosphorylation with IC
50
s of 0.3-0.5 μM and 0.5-1 μM for membrane autophosphorylation assays and Swiss 3T3 cells, respectively.
AG1295 (10 μM, 100 μM) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro.
Cell Viability Assay
| Cell Line: | Rabbit conjunctival fibroblasts cells |
| Concentration: | 1 μM, 10 μM, 100 μM |
| Incubation Time: | 3 days |
| Result: | Inhibited rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB. |
AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibition of PDGFR-beta-triggered tyrosine phosphorylation.
AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly reduces interstitial fibrosis as verified by a smaller Sirius-Red stained area and also by a reduced number of macrophages, and by the ED-A+ fibronectin deposition and the number of cells positive for alpha-smooth muscle actin.
| Animal Model: | Sprague-Dawley rats (240-270 g) |
| Dosage: | 12 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 14 or 21 days |
| Result: | Attenuated interstitial fibrosis in rat kidney after unilateral obstruction. |